Fidasimtamab, referred to as DLTV – 1504, represents the innovative avenue in the battle against multiple myeloma. It is a targeted molecule designed to together engage CD3-positive lymphocytes and https://fidasimtamab-recombinant718081.blogdigy.com/fidasimtamab-this-promising-treatment-in-advanced-myeloma-treatment-68850157